Jones Jonathan Brian Lloyd
CIK 1567657 · Chief Financial Officer · last filed 2017-03-27
Jones Jonathan Brian Lloyd is a Chief Financial Officer who has filed 7 SEC Form 4 insider transactions across 2 companies since 2013. The most recent filing shows the insider bought $30.0K of CUR on Mar 27, 2017. Across all open-market trades the lifetime net is +$55.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $12.8K across reported positions. 6 SEC filings were submitted jointly with COLUMBIA LABORATORIES INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CUR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOSTON, MA 02109
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALISADE BIO, INC. (CUR) Delisted | Chief Financial Officer | 393 | — | — | $40.0K | 3 | 2017-03-27 |
| CBRX | Vice President & CFO | 4,580 | $2.79 | $12.8K | $15.0K | 4 | 2014-03-12 |
Recent Filings
7 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-27 | PALISADE BIO, INC. (CUR) Delisted | Buy (P) | +5,455 | $30.0K | EDGAR |
| 2016-09-26 | PALISADE BIO, INC. (CUR) Delisted | Buy (P) | +31,250 | $10.0K | EDGAR |
| 2016-04-11 | PALISADE BIO, INC. (CUR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-12 | CBRX | Grant (A) | — | $0 | EDGAR |
| 2014-03-12 | CBRX | Exer (M) | +2,000 | $10.1K | EDGAR |
| 2013-11-26 | CBRX | Buy (P) | +1,580 | $10.0K | EDGAR |
| 2013-05-14 | CBRX | Buy (P) | +8,000 | $5.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.